文献速递姑息放疗与转移瘤乳腺癌放疗

乳腺癌骨寡转移患者立体定向体部放疗:欧洲多中心队列研究结果

Stereotactic body radiotherapy in patients with bone oligometastases from breast cancer - results from a European multicenter cohort study.
PubMed 文献 · Clin Transl Radiat Oncol · 2026-03-03

该欧洲多中心回顾性队列研究分析了2010至2024年间17个中心109例乳腺癌骨寡转移患者共147处骨转移灶接受SBRT的肿瘤学结局。中位随访29.6个月,中位处方剂量35 Gy/5次;GTVmean BED10≥50 Gy时1年/3年局部无复发生存率分别为98.1%和93.9%,不良事件少见、骨折率2.7%。结论认为SBRT耐受良好且有效,仍需前瞻性研究验证标准化SBRT方案在多学科管理中的作用。

要点

  • 乳腺癌骨寡转移SBRT局部控制良好,GTVmean BED10≥50 Gy时3年FFLR达93.9%。
  • 全身治疗与总生存改善相关(HR 0.22,p<0.001)。
  • 脊柱部位与无进展生存更差相关(HR 1.81,p=0.02),不良事件少见。

核心结论

  • 在该多中心回顾性队列中,乳腺癌骨转移灶SBRT耐受良好且有效。
  • 需前瞻性研究进一步验证这些发现并确定标准化SBRT方案在多学科管理中的作用。

研究设计与样本

  • 回顾性收集2010至2024年17个欧洲癌症中心乳腺癌骨转移接受SBRT的患者数据。
  • 共分析109例患者、147处骨转移灶,中位随访29.6个月(四分位距15.0-48.0)。
  • 分析治疗与剂量概念对局部无复发生存、总生存、无进展生存及安全性的影响。

主要发现

  • SBRT中位处方剂量为35 Gy,中位5次分割。
  • GTVmean BED10≥50 Gy时1年FFLR为98.1%(95%CI 92.7%-99.5%),3年为93.9%(95%CI 85.5%-97.5%)。
  • GTVmean BED10≥50 Gy时非脊柱骨转移1年/3年PFS为62.1%(95%CI 43.6%-76.0%)/26.7%(95%CI 11.0%-45.4%)。
  • GTVmean BED10≥50 Gy时脊柱骨转移1年/3年PFS为66.2%(95%CI 50.8%-77.8%)/35.8%(95%CI 21.3%-50.4%)。
  • 多变量分析中全身治疗与OS改善相关(HR 0.22;p<0.001),较高GTVmean BED10与PFS改善相关(HR 0.96;p<0.001),脊柱部位与PFS更差相关(HR 1.81;p=0.02)。

关键数值与推荐

  • SBRT中位处方剂量35 Gy、中位5次分割。
  • GTVmean BED10≥50 Gy与更优FFLR及PFS相关。
  • 不良事件少见,骨折发生率为2.7%。

临床怎么用

  • 对乳腺癌骨寡转移患者,可考虑SBRT作为转移灶导向放疗,尤其GTVmean BED10≥50 Gy时局部控制良好。
  • 脊柱骨转移患者PFS较差,需加强随访与多学科管理。
  • 全身治疗与OS改善相关,SBRT应纳入多学科综合治疗框架。

局限性

  • 本研究为回顾性多中心队列分析,存在回顾性设计固有局限。
  • 原文指出需前瞻性研究进一步验证这些发现。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: The interdisciplinary treatment concept for bone metastases (BoM) of oligometastatic breast cancer includes metastasis-directed radiotherapy. We evaluated oncological outcomes of BoM treated with stereotactic body radiotherapy (SBRT) in a large European cohort. MATERIAL AND METHODS: Data of breast cancer patients treated with SBRT for BoM between 2010 and 2024 at 17 European cancer centers were retrospectively collected. Treatment and dose concepts were analyzed regarding their impact on freedom from local recurrence (FFLR), overall survival (OS), progression-free survival (PFS), and safety profile. RESULTS: With a median follow-up of 29.6 months (interquartile range: 15.0-48.0), 109 patients with 147 BoM were analyzed. SBRT was performed with a prescribed dose of median 35 Gy in median 5 fractions. 1-/3-year FFLR for mean biologically effective dose (BED10) ≥ 50 Gy in the gross tumor volume (GTVmean) was 98.1% (95%-CI: 92.7%-99.5%) and 93.9% (95%-CI: 85.5%-97.5%), respectively. For GTVmean BED10 ≥ 50 Gy, 1-/3-year PFS was 62.1% (95%-CI: 43.6%-76.0%)/26.7% (95%-CI: 11.0%-45.4%) for non-spine BoM and 66.2% (95%-CI: 50.8%-77.8%)/35.8% (95%-CI: 21.3%-50.4%) for spine BoM. In multivariable analysis, systemic therapy (HR [hazard ratio] 0.22; p < 0.001) was associated with improved OS, while higher GTVmean BED10 (HR 0.96; p < 0.001) was associated with improved PFS and spine localization with worse PFS (HR 1.81; p = 0.02). Adverse events were rare, with fracture rates of 2.7%. CONCLUSION: In this multicenter retrospective cohort analysis, SBRT of BoM from breast cancer was a well-tolerated, effective treatment. Prospective studies are needed to investigate these findings further and determine the role of standardized SBRT concepts in the multidisciplinary management of oligometastatic breast cancer.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Schäfer S, Seiler I, Kästner L, et al. Stereotactic body radiotherapy in patients with bone oligometastases from breast cancer - results from a European multicenter cohort study. Clin Transl Radiat Oncol. 2026. PMID: 41853739. doi:10.1016/j.ctro.2026.101142

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。